 |
| |
 | |
Recommendation
| Note that metformin treatment in overweight patients with newly diagnosed diabetes is associated with reductions in mortality rates, MI, and diabetes complications.
|
| |
Evidence:
- A subgroup of over 700 overweight subjects in the UKPDS were treated with metformin as their intervention. Metformin treatment was associated with significant reductions in all-cause mortality (RRR, 0.33; NNT, 14), diabetes-related mortality (RRR, 0.42; NNT, 19), MI (RRR, 0.36; NNT, 14), and diabetes-related outcomes (RRR, 0.32; NNT, 10) (78).
| |
Comments:
| | FAQs |
|
| Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Screening for Type 2 Diabetes
> Effectiveness/Harms of Early Treatment
